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Background: Depression is the most common co-morbidity for people with Multiple Sclerosis (MS); irrespective of
disease severity, depression has the greatest impact on quality of life. An emerging paradigm in the treatment of
depression is lifestyle medicine. There is significant potential to prevent and treat depression through modification of
lifestyle risk factors for people with MS. This study sought to understand the association between lifestyle risk factors,
medication and depression risk through the analysis of self-reported data from a large international sample of people
with MS.
Methods: This cross-sectional analysis recruited a total of 2459 participants via Web 2.0 platforms. Survey data included
socio-demographics; a range of lifestyle risk factors; medication; disease variables and depression risk using the Patient
Health Questionnaire-2 (PHQ-2).
Results: In total approximately one fifth (19.3%) of our sample screened positive for depression (PHQ-2 score ≥3). Several
demographic factors were significantly associated with this depression risk in bivariate analysis. Regression analyses
showed that poor diet, low levels of exercise, obesity, smoking, marked social isolation and taking interferon were
associated with greater depression risk. Participants who supplemented with omega 3s, particularly flaxseed oil, had
frequent fish consumption, supplemented with vitamin D, meditated, and had moderate alcohol consumption had
significantly reduced depression risk.
Conclusions: This study demonstrates a significant association between modifiable lifestyle factors and depression risk.
Planned longitudinal follow up may clarify causality. Clinicians and people with MS should be aware of the wide range of
modifiable lifestyle factors that may reduce depression risk as part of a comprehensive secondary and tertiary preventive
medical approach to managing MS.
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Multiple sclerosis (MS) is a chronic autoimmune, inflam-
matory and demyelinating disease of the central nervous
system. Symptoms can include motor and sensory deficits,
ataxia, visual impairment, bladder and bowel incontin-
ence, cognitive impairment, pain and fatigue. However for* Correspondence: keryn.taylor@svha.org.au
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unless otherwise stated.people with MS it is depression, irrespective of disease se-
verity that has the greatest impact on quality of life [1].
Depression is the most common psychiatric illness and
co-morbidity for people with MS, who are also at higher
risk of suicide and self-harm than others in the population
[2]. Severity of depression is a risk factor associated with
suicide risk. For people with MS, the lifetime prevalence of
a major depressive disorder is 50%, although an Australian
study estimated an even higher rate of 67% [3]. The annual
incidence is estimated to be 20% [4].
Although the high prevalence of depression in people
with MS is widely acknowledged, depression is under-td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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depressed have increased use of outpatient and inpatient
services, require comprehensive rehabilitative periods, and
require more unsalaried care than those without depression
[6]. The timely and effective treatment of depression for
people with MS is vital. Treatment should be provided by
mental health professionals in collaboration with general
MS care [7].
A recent Cochrane review of pharmaceutical treatment
of depression in MS failed to find any antidepressant
medication that was significantly effective in treating de-
pression in this patient group [8]. In fact a recent review
of MS literature concluded there are no evidence based
guidelines for either pharmacological or psychological
treatments for people with MS and depression [9].
An emerging paradigm in the treatment of depression
is lifestyle medicine. There is clear evidence that lifestyle
factors are linked to the pathogenesis of mood disorders
[10]. Many lifestyle factors are modifiable yet there is
often little consideration of this treatment strategy, and
pharmacological and psychological therapies remain the
first line treatment choices [10]. A recent randomized
controlled trial showed that modification of lifestyle fac-
tors (diet, sunlight exposure, exercise and sleep patterns)
was an effective treatment strategy for depression [11].
Evidence-based recommendations can also be made for
the use of mindfulness-based meditation as a treatment
intervention for depression in people with MS [12].
There is strong evidence that smoking [13] and lack of
social support are risk factors for depression [14,15].
The evidence for lifestyle medicine encourages an inte-
grative approach whereby lifestyle modification is a rou-
tine part of prevention and treatment for depression.
Lifestyle medicine for depression brings additional bene-
fits to general health, particularly in reducing the likeli-
hood of other high prevalence chronic western lifestyle
related diseases such as cardiovascular disease and dia-
betes [10,13,16].
There appears to be significant potential to prevent
and treat depression through modification of lifestyle
risk factors for people with MS, although data are
currently limited. In the Health Outcomes and Lifestyle
Interventions in a Sample of People with Multiple
Sclerosis (HOLISM) Study, we sought to understand the
association between lifestyle risk factors amenable to
modification and disease outcomes in general, through
the analysis of self-reported data from a large inter-
national sample of people with MS. In this current
study, part of the wider HOLISM research, we examined
depression in particular, and its association with modifi-
able lifestyle risk factors and medication use, in order to
better understand the potential for a secondary and ter-
tiary preventive medical approach to managing depres-
sion in MS [17-20].Methods
Participants and recruitment
The methodology for the HOLISM Study has previously
been documented in detail [17]. In summary, participants
were recruited via posting a link to the survey on Web 2.0
platforms that engaged people with MS. Participants com-
pleted a survey via SurveyMonkey® that examined their
health and lifestyle behaviours, self-reported disability, dis-
ease activity, quality of life and depression, among other
factors. Participants were eligible for the study if they were
over 18 years of age and had been diagnosed with MS by a
medical doctor. Participants were presented with an infor-
mation page and selected “I agree” at the bottom of the
page to provide consent before entering the survey. Ethics
approval was granted by St Vincent’s Hospital Melbourne
Human Research Ethics Committee (LRR 055/12).
Data collection and tools used
For this study the survey data included items assessing
the following: socio-demographics; diagnostic history;
level of disability; co-morbidities; fatigue; and depression;
as well as a range of lifestyle and health behaviours.
Demographic data
Age, age at diagnosis, type of MS, gender, marital status,
number of children, education level, employment status,
weight and height were assessed and body mass index
(BMI) was calculated by dividing weight (in kilograms) by
height2 (in centimeters) and recoded into categories ac-
cording to the World Health Organization (WHO) [21].
Those with BMI below 18.5 were categorized as under-
weight, those with BMI of 18.5 and up to 25 normal, BMI
of 25 and up to 30 overweight and BMI of 30 and over
obese.
Depression
The Patient Health Questionnaire (PHQ-9) is a screening
tool for depression, which has previously been validated in
people with MS [22]. In our study we used the Patient
Health Questionnaire depression module short version
(PHQ-2). The PHQ-2 is scored in response to the ques-
tion: ‘Over the past 2 weeks, how often have you been
bothered by any of the following problems: Little interest
or pleasure in doing things; Feeling down, depressed, or
hopeless’ as follows: Not at all [0], Several days [1], More
than half the days [2], Nearly every day [3]. The PHQ-2 is
a shortened form of the PHQ-9 which has shown good
criterion and construct validity. The PHQ-2 has a re-
ported specificity of 92% and sensitivity of 83% for major
depression with a score ≥3 [23]. This cut off was used in
our analysis as a positive screen for depression risk. In
addition, participants were asked to indicate whether they
had a diagnosis of depression, whether they were receiving
treatment for it, and whether depression limited their
Taylor et al. BMC Psychiatry 2014, 14:327 Page 3 of 12
http://www.biomedcentral.com/1471-244X/14/327daily activities. The same questions were asked about an
anxiety diagnosis. This question format was derived from
the Self-Administered Comorbidity Questionnaire (SCQ)
used to assess physical co-morbidities in the survey.
Fatigue
The Fatigue Severity Scale (FSS) consists of nine fatigue-
related statements rated on a seven-point scale from ‘dis-
agree’ to ‘agree’ [24]. We used a mean score ≥4 to indicate
clinically significant fatigue [25-27].
Disability
The Patient-Determined Disease Steps (PDDS) is a self-
reported surrogate tool to the Expanded Disability Status
Scale (EDSS). It is an ordinal scale from O (normal) to 8
(bed bound) and has good correlation with the EDSS. It is
also used as a practical tool to assess changes in people
with MS across time [28] and has been used in numerous
studies including the North American Research Commit-
tee on MS (NARCOMS) registry [29-31]. Due to a low
number of cases in the ‘bed bound’ category, participants
scoring 7 (‘wheelchair/scooter’) and 8 were grouped to-
gether to enable meaningful analysis. Analyses included
people with all types of MS.
Co-morbidities
We used the SCQ to assess co-morbidities in the ab-
sence of access to participants’ medical records. The
SCQ determines if the co-morbidity limits activities and
whether treatment is received. The SCQ has previously
been used in a study of people with MS [32]. In our
study, two arthritic co-morbidities were combined into
one. All listed conditions were summed to determine an
estimate of the number of co-morbidities each partici-
pant reported. Participants were then categorised as hav-
ing: ‘none’, ‘1’, ‘2’, ‘3’, ‘4’, ‘5 or more’, co-morbidities.
Dietary habits
For dietary assessment we used the Diet Habits Ques-
tionnaire (DHQ). The DHQ is a 24 item tool that has
previously been used in an Australian cardiac population
[33] and in the HOLISM study research on diet in MS
[17-20]. We removed four items assessing salt use and
alcohol intake. The remaining 20 items were scored
from 1–5, giving rise to a summary score with a possible
range of 20–100, with higher scores indicating more
healthy dietary habits. Participants were grouped into
quartiles, based on their summary score.
Medication use
We used a researcher-generated list of disease modifying
drugs (DMDs) and common MS drugs. We asked for
specific details including past and current use and dur-
ation of use. For the purpose of analysis, participantswere categorised according to whether they currently
took one of the interferons (one of the currently licensed
interferon beta preparations: Avonex, Rebif, Betaferon or
Betaseron), a disease modifying drug other than an inter-
feron, or “other” (including those who took a non dis-
ease modifying drug or who took none). Interferon use
was analysed individually given its previously reported
association with higher rates of depression [34].
Vitamin D supplementation
We explored participants’ current vitamin D supplemen-
tation and calculated an average daily dosage. Partici-
pants were grouped as ‘none’, ‘< 5000 international units’
(IU) or ≥5000 IU.
Omega-3 fatty acid supplementation
We assessed the type and average daily dose of omega-3
fatty acid supplementation used in the last 12 months.
Types of omega-3 included flaxseed oil, fish oil, high
strength fish oil, and ‘other’. Participants were grouped
according to whether they took omega-3 supplementa-
tion (yes/no) and the type (‘flaxseed oil’, ‘fish oil and high
strength fish oil’, ‘both’ or ‘none’). These comparisons
were made based on findings from our previous work on
omega-3s [20].
Exercise
We used the International Physical Activity Question-
naire (IPAQ), which assesses the duration and frequency
of vigorous and moderate physical activity, walking and
sitting over the last 7 days. The IPAQ has been exten-
sively validated, including in MS populations [35,36].
Participants were categorised as low active, moderate ac-
tive, or high active, as defined by the IPAQ scoring
instructions.
Meditation
We asked participants how often they meditated on an
average weekly basis. Response options were categorised
for the purpose of analysis as ‘never’, ‘less than once per
week’, ‘1–4 times per week’ or ‘5 or more times per week’.
Social support
We used the Single Item Measure of Social Support
(SIMSS) to determine how many people provided sup-
port to participants. It has previously been used in sev-
eral studies involving cancer patients [37,38]. Response
options were: none, 1 person, 2–5 people, 6–9 people, or
10 or more people. For the purpose of our study, the lat-
ter two categories were collapsed together.
Data analysis
IBM SPSS Statistics 22.0 was used to analyse the data.
Univariate analyses were performed and continuous data
Table 1 Demographics and characteristics
Median IQR
Age (years) 45 (38–53)
Years since diagnosis 6 (3–12)
Age at diagnosis (in years) 37 (30–45)
N %
Gender Male 388/2201 17.6
Female 1813/2201 82.4
Marital status Married/cohabiting/partnered 1642/2194 74.8
Single 304/2194 13.9
Separated/Divorced/Widower 248/2194 11.3
Children None 682/2196 31.1
One or more 1514/2196 68.9
Education No school/primary/secondary 533/2216 24.1
Vocational training 355/2216 16.0
Bachelor degree 808/2216 36.5
Postgraduate 520/2216 23.5
Employment status Part time 473/2220 21.3
Retired due to disability 508/2220 22.9
Work full time 729/2220 32.8
Other* 510/2220 23.0
Type of MS Benign 95/2217 4.3
Relapsing-remitting 1359/2217 61.3
Primary progressive 160/2217 7.2
Secondary progressive 256/2217 11.5
Progressive relapsing 46/2217 2.1
Unsure/other 301/2217 13.6
Disability Normal 714/2218 32.2
Mild disability 342/2218 15.4
Moderate disability 159/2218 7.2
Gait disability 354/2218 16.0
Early cane 245/2218 11.0
Late cane 168/2218 7.6
Bilateral support 135/2218 6.1
Wheelchair/Scooter 98/2218 4.4
Bedridden 3/2218 .1
*Includes stay at home parents, full time students, unemployed (seeking and
not seeking employment), retired due to age and other. IQR, inter quartile
range.
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egorical data using number and percentage. The denom-
inator for each item varied due to variation in the
number of participants completing each item, as per tab-
ulated results.
Bivariate analyses were used to explore the relation-
ship between socio-demographic factors, disease-specific
variables, and the depression outcome measure (PHQ-2)
to determine factors that should be included as covari-
ates in regression modeling.
The complexity of interactions between the sociodemo-
graphic, health-related and lifestyle variables make it diffi-
cult to determine which lifestyle variables are uniquely
associated with depression. Multivariate analysis examined
a range of modifiable risk factors (‘exposure variables’, i.e.
diet, exercise, vitamin D) and their association with
screening positive for depression. Medication use could be
regarded as a ‘modifiable risk factor’ for depression [34]
and was therefore examined as an exposure variable.
Binary logistic regression was used to predict depres-
sive risk (those scoring ≥3). For each modifiable risk fac-
tor individual models were derived adjusting for years
since diagnosis, numbers of comorbidities, level of dis-
ability, clinically significant fatigue, age, gender and level
of education. Type of MS was highly related with level
of disability and we therefore chose to include only level
of disability in the model. To maintain simplicity, we did
not include employment in this model due to the num-
ber of categories within this variable. Because depression
and fatigue have a complex relationship in people with
MS, and fatigue may mediate depressive features [39],
after controlling for fatigue as a potential confounder in
multivariate analyses, we additionally compared models
both with and without fatigue. There was negligible (up
to approximately 10% in either direction) change to par-
ameter estimates for all lifestyle variables when fatigue
was removed from the model, and hence these results
are not reported.
Results
The demographics of this cohort (Table 1) have been de-
scribed in detail in previous papers [17-20]. A high per-
centage (90.1%) of our sample answered the PHQ-2
screening questions for depression, Table 1 shows the
demographics for the 2225 participants who completed
the PHQ-2. The majority originated from the United
States of America, Australia and the United Kingdom,
with participants overall representing 54 different coun-
tries. Participants were mainly female (82.4%) and mid-
dle aged (median age 45 years). The majority were well
educated holding a bachelor (36.5%) or post-graduate
degree (23.5%), and working either full time (32.8%) or
part time (21.3%), with almost a quarter retired due to
disability. Most had a partner (74.8%) and children(68.9%). Participants had a median age of 37 years at
diagnosis, on average had been recently diagnosed
(45.2% within the last 5 years) and had mild disability
(54.8% had PDDS scores 0–2). The majority (61.3%) had
relapsing remitting MS.
In total approximately one fifth (19.3%, N = 429) of
our sample screened positive for depression (depression
risk). Overall, 18.9% (N = 420) reported little interest or
pleasure in doing things and 14.5% (N = 322) reported
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days or nearly every day. Nearly one third (30.9%, N =
686) of respondents reported depression as a current co-
morbidity and of those, 70.6% (N = 484) reported receiv-
ing treatment for the condition and 39.1% (N = 268)
reported depression limiting their activities. Of the
whole sample, 21.8% (N = 484) were taking a prescrip-
tion medication for depression. Nearly 10% (9.6%, N =
47) of those taking prescription medication for depres-
sion stated that they did not have the condition.
Of those who screened positive for depression, 92.9%
(N = 379) had a mean score of 4 or above on the FSS, in-
dicating clinically significant fatigue.
Demographic factors associated with depression risk
Regression analysis indicated that for every one year in-
crease in age, participants had approximately 1.1% re-
duction in the odds of screening positive for depression
(OR 0.989, 95%CI 0.979–0.999; p < 0.032). For every one
year increase since diagnosis, participants had approxi-
mately 1.4% increase in the odds of screening positive
for depression (OR 1.014, 95%CI 1.000–1.028; p = .049).
For every one year increase at age of diagnosis, partici-
pants had a 2.0% decrease in the odds of screening posi-
tive for depression (OR 0.980, 95%CI 0.969–0.991;
p < 0.001). Participants with a secondary school educa-
tion and those with vocational training had around twice
the odds of screening positive for depression of those
with a postgraduate degree (Table 2). Participants who
were separated, divorced or widower had 1.7 times
greater odds of screening positive for depression than
those married or co-habiting. Participants who were un-
employed or retired due to disability had around twice
the odds of screening positive for depression of those
working full-time. Those with moderate or severe dis-
ability also had around twice the odds of screening posi-
tive for depression compared to those with mild
disability. Type of MS was significantly associated with
depression risk in that people with progressive relapsing
MS were almost 2.5 times more likely to screen positive
for depression than those with relapsing-remitting MS.
There was a clearly increasing depression risk as the
number of comorbidities increased and those with clin-
ically significant fatigue were 9 times more likely to
screen positive for depression. Participants’ gender and
whether or not they had children was not significantly
associated with depression risk (data not shown).
Modifiable lifestyle factors
A number of modifiable lifestyle factors were signifi-
cantly associated with depression risk in regression ana-
lyses adjusted for years since diagnosis, number of
comorbidities, level of disability, clinically significant fa-
tigue, age, gender, level of education and marital status.Figure 1 shows associations between depression screen
and vitamin D supplementation, fish consumption, diet-
ary habits and physical activity. Table 3 shows crude and
adjusted odds ratios with 95% confidence intervals.
In summary, never smokers had the lowest odds of
screening positive for depression, with increasing odds
for former smokers, and greatest odds for current
smokers. Participants who had moderate alcohol intake
had significantly lower odds of screening positive for de-
pression compared to participants with low alcohol in-
take. There was a dose-response effect with increasing
levels of exercise associated with lower odds of screening
positive for depression. Taking any vitamin D supple-
ment was associated with lower odds of screening posi-
tive for depression, but taking at least 5,000 IU daily was
associated with the greatest odds. Participants who sup-
plemented with omega 3s had significantly reduced odds
of screening positive for depression. Those supplement-
ing with flaxseed oil had greater reduction in odds than
those supplementing with fish oil. There was a clear
dose-response effect for frequency of fish consumption,
with most frequent fish consumers having the least odds
of screening positive for depression. Meditation was
associated with lower odds of screening positive for
depression for those who meditated once or more per
week. The odds of screening positive for depression
increased with increasing social isolation but was only
significant for those with very marked social isolation
(none or one support person). Obese participants had
significantly greater odds of screening positive for
depression compared to those with a normal BMI. There
was a clear dose-response effect for increasingly poor
diet being associated with greater odds of screening
positive for depression. Participants taking one of the
interferons had significantly increased odds.
Discussion
The prevalence of depression for people with MS is con-
siderably higher than that of the general population [40]
and higher than with other chronic illnesses [41,42]
probably because of the multifactorial nature of depres-
sion in MS. While it may be reactive to the diagnosis of
a chronic illness, depression in MS is also likely to be
endogenous, partly based on the link with sclerotic path-
ology in specific neurological territories [43]. In a study
controlling for disease-related variables and demograph-
ics, people with MS had three times the risk of depres-
sion compared to those with rheumatoid arthritis,
suggesting that these differences could in part be attrib-
uted to the biological impact of the disease process in
MS. [41] Additionally there is a strong link between gen-
etics and depression in the general population when
people with MS are excluded; however, for people with
MS who have depression there is not a clear genetic
Table 2 Odds ratios for risk of depression for demographic and disease factors
Variable Groups Positive depression screen^, N(%) p Unadjusted OR p
Education Postgraduate degree 70/ 520 (13.5)† <0.001 1.0 -
Bachelor degree 137 808/(17.0)† 1.31 (0.96–1.79) 0.087
Vocational training 84/ 355 (23.7)* 1.99 (1.40–2.83) <0.001
No school/primary/secondary 138/ 533 (25.9)* 2.25 (1.64–3.09) <0.001
Marital status Married/partnered/cohabitating 285/ 1642 (17.4)† 0.001 1.0 -
Single 73/ 304 (24.0)* 1.51 (1.12–2.02) 0.006
Separated/divorced/widow(er) 64/ 248 (25.8)* 1.66 (1.21–2.26) 0.002
Employment Work full time 119/ 729 (16.3)† <0.001 1.0 -
Work part time 66/ 473 (14.0)† 0.83 (0.60–1.15) 0.266
Stay at home parent/carer 26/ 172 (15.1)† 0.91 (0.58–1.45) 0.698
Unemployed 46/167 (27.5)* 1.95 (1.32–2.89) 0.001
Retired due to disability 150/ 508 (29.5)* 2.15 (1.63–2.82) <0.001
Retired due to age 6/ 70 (8.6) † 0.48 (0.20–1.14) 0.095
Other (includes student) 15/ 101 (14.9)† 0.89 (0.50–1.60) 0.706
Disability Mild 169/ 1215 (13.9)† <0.001 1.0 -
Moderate 199/ 767 (25.9)* 2.17 (1.73–2.73) <0.001
Severe 59/ 236 (25.0)* 2.06 (1.74–2.89) <0.001
Type of MS Relapsing-remitting 252/ 1359 (18.5)† 0.015 1.0 -
Benign 10/ 95 (10.5) 0.52 (0.27–1.01) 0.053
Primary progressive 35/ 160 (21.9) 1.23 (0.83–1.83) 0.309
Secondary progressive 56/ 256 (21.9) 1.23 (0.89–1.71) 0.214
Progressive relapsing 16/ 46 (34.8)* 2.34 (1.26–4.36) 0.007
Unsure/other 58/ 301 (19.3) 1.05 (0.76–1.44) 0.770
Number of comorbidities None 53/ 737 (7.2)† <0.001 1.0 -
One 86/ 583 (14.8)† 2.23 (1.56–3.21) <0.001
Two 110/ 452 (24.3)* 4.15 (2.92–5.91) <0.001
Three 103/ 259 (39.8)* 8.52 (5.86–12.39) <0.001
Four 40/ 110 (36.4)* 7.38 (4.57–11.90) <0.001
Five or more 36/ 80 (45.0)* 10.56 (6.27–17.79) <0.001
Clinically significant fatigue No 29/ 732 (4.0)† <0.001 1.0 -
Yes 379/ 1393 (27.2)* 9.06 (6.14–13.38) <0.001
*denotes overrepresentation and † denotes underrepresentation ^ PHQ-2 score ≥3. Bold denotes statistically significant.
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uting factors [44,45].
Depression symptoms increase during a relapse, how-
ever they do not typically resolve following recovery but
may become persistent [46]. Depression can also exacer-
bate or be implicated in other symptoms of MS includ-
ing fatigue (2), cognitive processing and working
memory [47,48], as well as the experience of pain symp-
toms (4). In our study however, fatigue did not appear to
mediate the effects of depression, and its inclusion in re-
gression modelling had little impact on the observed
associations.
The high prevalence of depression in people with MS
and its likely reactive and endogenous mechanisms areimportant for two reasons. Firstly they highlight the
need for screening, assessment and treatment of depres-
sion in people with MS. Secondly, by drawing attention
to the direct disease impact on depression, patients may
more readily be able to overcome the self-stigma of de-
pression and seek vital treatment [41].
It is important to alleviate depressive symptoms to
improve quality of life but also to avoid worsening of
physical health outcomes. A growing body of evidence
highlights the pro-inflammatory immunological changes
seen in depression and the link to disease activity in MS.
Depression increases pro-inflammatory cytokines and
inflammation, thereby worsening MS [48] and is asso-
ciated with an increase in interferon secretion by T
Figure 1 Associations between lifestyle factors and depression screen.
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found to be associated with depression risk in our study
have also been shown to modulate inflammation, such
as smoking, exercise and meditation [50-52].
It is important to prevent and treat depression to optimize
adherence to disease modifying therapies [4,53] and to
monitor people with MS for the potential iatrogenic effects
of disease modifying medication leading to depression (4).
In this context of negative mental, physical and quality
of life consequences of depression, it is important for cli-
nicians and researchers to better understand the lifestyleand medication risk factors that may lead to depression
in people with MS, and that may be amenable to modifi-
cation. Through a comprehensive investigation of modi-
fiable risk factors for depression in a large international
sample of people with MS, our study is an important
addition to the literature. We have shown strong and
highly significant associations between modifiable life-
style factors and medication use and depression risk,
providing valuable information for clinicians and people
with MS alike about the key factors that may be modi-
fied to reduce depression risk.
Table 3 Crude and adjusted odds ratios, with 95% confidence intervals, for modifiable lifestyle risk factors and risk of
depression
Positive depression screen^, n/N(%) p Crude OR (95% CI) A OR (95% CI)
Smoking Never 153/1072 (14.3) <0.001 1.00 (reference) 1.00 (reference)
Former 178/890 (20.0) 1.50 (1.19–1.90)** 1.54 (1.18–2.03)**
Current 96/257 (37.4) 3.58 (2.64–4.86)*** 2.29 (1.60–3.27)***
Alcohol Low 310/1354 (22.9) <0.001 1.00 (reference) 1.00 (reference)
Moderate 113/834 (13.5) 0.53 (0.42–0.67)*** 0.73 (0.55–0.96)*
High 4/17 (23.5) 1.04 (0.34–3.20) 1.35 (0.38–4.74)
Exercise Low 257/909 (28.3) <0.001 1.00 (reference) 1.00 (reference)
Moderate 104/701 (14.8) 0.44 (0.34–0.57)*** 0.58 (0.43–0.78)***
High 63/591 (10.7) 0.30 (0.23–0.41)*** 0.51 (0.36–0.72)***
Vitamin D None 117/389 (30.1) <0.001 1.00 (reference) 1.00 (reference)
1- 5000 IU 231/1324 (17.4) 0.49 (0.38–0.64)*** 0.57 (0.43–0.77)***
> 5000 IU 64/439 (14.6) 0.40 (0.28–0.56)*** 0.47 (0.32–0.70)***
Omega 3 No 218/791 (27.6) <0.001 1.00 (reference) 1.00 (reference)
Yes 205/1420 (14.4) 0.44 (0.36–0.55)*** 0.58 (0.45–0.75)***
Omega 3 type None 218/791 (27.6) <0.001 1.00 (reference) 1.00 (reference)
Fish oil^ 127/778 (16.3) 0.51 (0.40–0.66)*** 0.64 (0.48–0.85)**
Flaxseed oil 21/200 (10.5) 0.31 (0.19–0.50)*** 0.48 (0.28–0.82)**
Both fish oil and flaxseed oil 46/388 (11.9) 0.35 (0.25–0.50)*** 0.49 (0.33–0.72)***
Fish consumption Less than once per week 180/638 (28.2) <0.001 1.00 (reference) 1.00 (reference)
1–2 times per week 173/884 (19.6) 0.62 (0.49–0.79)*** 0.71 (0.54–0.93)*
3 or more days per week 75/696 (10.8) 0.31 (0.23–0.41)*** 0.48 (0.34–0.67)***
Meditation Never 241/1058 (22.8) <0.001 1.00 (reference) 1.00 (reference)
Less than once per week 99/493 (20.1) 0.85 (0.66–1.11) 0.86 (0.64–1.17)
1–4 times per week 56/440 (12.7) 0.49 (0.36–0.68)*** 0.52 (0.36–0.75)***
5 or more times per week 29/227 (12.8) 0.50 (0.33–0.75)** 0.47 (0.29–0.75)**
Social support 6 or more 40/299 (13.4) <0.001 1.00 (reference) 1.00 (reference)
2–5 215/1316 (16.3) 1.26 (0.88–1.82) 1.11 (0.74–1.66)
1 134/475 (28.2) 2.54 (1.73–3.75)*** 2.42 (1.55–3.77)***
None 34/111 (30.6) 2.86 (1.70–4.82)*** 2.43 (1.32–4.47)**
Body Mass Index Normal 176/1183 (14.9) <0.001 1.00 (reference) 1.00 (reference)
Underweight 16/92 (17.4) 1.21 (0.69–2.11) 0.97 (0.50–1.88)
Overweight 113/504 (22.4) 1.65 (1.27–2.15)*** 1.23 (0.91–1.67)
Obese 116/421 (27.6) 2.18 (1.67–2.84)*** 1.47 (1.08–2.01)*
Dietary habits Upper (fourth) quartile 44/541 (8.1) <0.001 1.00 (reference) 1.00 (reference)
Third quartile 75/488 (15.4) 2.05 (1.38–3.04)*** 1.65 (1.07–2.54)*
Second quartile 116/502 (23.1) 3.39 (2.34–4.92)*** 2.25 (1.48–3.41)***
Lower (first) quartile 150/499 (30.1) 4.86 (3.38–6.98)*** 2.73 (1.81–4.11)***
Medication No DMD 187/1094 (17.1) .004 1.00 (reference) 1.00 (reference)
Interferon 104/424 (24.5) 1.58 (1.120–2.07)** 1.47 (1.07–2.02)*
DMD not IFN 138/706 (19.5) 1.18 (0.92–1.05) 1.20 (0.90–1.60)
AOR: Adjusted odds ratios of screening positive for depression adjusted for years since diagnosis, number of comorbidities, level of disability, clinically significant
fatigue, age, gender, marital status and level of education.
* < 0.05, ** < 0.01, *** < 0.001.
^ PHQ-2 score ≥3. Bold denotes statistically significant.
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ated with higher odds of screening positive for depression
were lower educational status, unemployment or retire-
ment due to disability and being separated or divorced.
Those who were younger, diagnosed for longer, with more
relapses over the previous year, more severe disability,
with a progressive relapsing type of MS, and a higher
number of comorbidities also had higher odds of screen-
ing positive for depression. These findings are consistent
with recent research and underscore the importance of so-
cial interventions for people with MS such as support to
maintain employment [54].
In line with previous research in MS and other neuro-
logical disorders [14,15], our data showed a very strong re-
lationship between less social support and increased odds
of screening positive for depression. Participants with no
or little social support had nearly 2.5 times the odds com-
pared to those with high levels of support; this was one of
the strongest associations of all the variables we studied in
regression analysis. Self-management programs that offer
the opportunity for group support may help reduce de-
pression risk in people with MS, as previously shown in
follow up studies demonstrating improved mental health
after residential group programs [55,56].
Diet had a very strong association with depression risk,
both clinically and statistically, with a clear dose-
response effect of increasing odds of screening positive
for depression with worsening diet. Those with very
poor diet had a nearly threefold increase in odds. Our
data are consistent with systematic reviews of observa-
tional and prospective studies showing that healthy diet-
ary patterns positively influence depression in the
general population [57,58]. Given other beneficial effects
of healthy diet in MS [18] and generally [59], it is im-
portant for clinicians to provide dietary advice as a key
component of depression risk management in MS.
As in the general population [60], smokers in our study
had approximately two and a half times greater odds of
screening positive for depression than non-smokers, while
former smokers also had higher odds compared to partici-
pants who had never smoked. This finding is also consist-
ent with the pattern observed for health-related quality of
life (HRQOL), including emotional well-being and mental
health composite scores, seen in people with MS [19] and
in the general population [61]. The proposed immuno-
modulatory or neurotoxic effects of smoking [62] may
share common aetiological pathways in depression for
people with MS [63].
Exercise was strongly associated with depression risk,
again with a dose-response effect. Participants with high
levels of exercise had half the odds of screening positive for
depression while those with moderate levels had a lesser
reduction. People with MS who regularly participate in
physical activity are more likely to have fewer depressivesymptoms and to have reducing depressive symptoms
across time [64,65]. Again, given the generally beneficial ef-
fects of exercise, and particularly for those people with MS
[65], clinicians should offer this advice to people with MS.
Similarly, the odds of screening positive for depression
was roughly halved in participants supplementing with
omega 3 fatty acids, with a greater reduction for flaxseed
oil than for those supplementing with fish oil alone or in
combination with flaxseed oil, in line with our previously
reported data on relapse rate reductions [20]. People
consuming fish more frequently had similar reductions
in the odds of screening positive for depression, with a
dose-response effect, again in line with previously re-
ported benefits to other health outcomes in people with
MS [20]. Epidemiological research indicates that low
omega 3 fatty acid consumption is associated with
higher rates of depression in the general population [66].
Animal and clinical studies show that omega 3s have
strong anti-inflammatory properties and may be effective
in modulating inflammatory diseases such as MS and
the associated depression [67]. Our data strongly sup-
port a role for omega 3 supplementation in reducing de-
pression risk in people with MS, in addition to its clear
association with reduced risk of relapse [20].
Vitamin D supplementation in combination with flu-
oxetine was more effective than fluoxetine alone in redu-
cing depressive symptoms in a randomized controlled
trial of patients with depression in the general popula-
tion [68]. For people with MS, low vitamin D is signifi-
cantly associated with depressive symptoms [69]. Our
data support a role for vitamin D supplementation in re-
ducing depression risk for people with MS, with a halv-
ing of odds of screening positive for depression for
participants taking more than 5000 IU of vitamin D
daily, and a dose-response effect. A dose of at least
5000 IU daily has previously been suggested as an opti-
mal dose for people with MS [70].
The relationship between obesity and depression is bi-
directional with inflammation playing an intermediary
role. Adipocytes secrete tumour necrosis factor alpha and
interleukin 6 leading to increased leukocytes and chronic
inflammation. Inflammation in turn is linked to many
lifestyle-related diseases such as MS, diabetes and cardio-
vascular disease [71]. Obese participants in our study had
1.5 times greater odds of screening positive for depression
than those with normal BMI. Weight loss is potentially an
effective intervention to improve both mental and physical
health, particularly for people with MS [72], and clinicians
treating people with MS should incorporate this into an
overall preventive management plan.
Our study failed to detect any increased odds of screen-
ing positive for depression associated with alcohol intake
in people with MS, although may have been limited in
power because of small numbers consuming alcohol in
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tern of association between level of alcohol use and de-
pression risk, with moderate alcohol intake associated
with almost 1.5 times reduced odds of screening positive
for depression compared to low levels of alcohol use. This
pattern is in line with data observed for HRQOL in people
with MS [19] and in mortality data for other chronic ill-
nesses [45] supporting the external validity of our study’s
self-reported data; we did not detect any signal suggesting
significant health risks for people with MS drinking mod-
erate amounts of alcohol.
Recent meta-analysis of meditation programs shows an
improvement in depression, HRQOL mental health com-
posite scores and psychological stress in the general popula-
tion [73]. Consistent findings from a randomized controlled
trial showed that mindfulness based interventions improved
depression and HRQOL at six months follow up in people
with MS, while control subjects had a worsening of symp-
toms [12,74]. In line with these studies, we have shown a
halving of the odds of screening positive for depression in
people with MS who meditated once or more per week.
Numerous neurobiological mechanisms underpin the bene-
fits of meditation for mental health, including attention and
emotional regulation, cognitive re-evaluation and body
awareness. Mindfulness meditation also holds benefit for
physical health for people with MS by improving immune
function and reducing inflammation [75].
Finally, while the interferons have been shown in random-
ized controlled trials to reduce relapse rates modestly, there
has been concern about their side effects. Interferons may
worsen depressive symptoms in people with and without
pre-existing depression [34]. An uncommon, yet serious ad-
verse effect of interferon treatment for people with MS is se-
vere depression with active suicidal ideation and suicide
attempts [34]. Our finding that participants taking interferon
had nearly 50% increased odds of screening positive for
depression, while those taking other disease-modifying
medications did not appear to be at heightened risk of de-
pression. This highlights the need for clinicians to carefully
consider, assess and monitor patients’ mental health when
suggesting medication choices, and carefully communicating
potential risks to their patients.
Limitations
Overall 19.3% of our study’s participants screened positive
for depression. Current literature suggests the annual inci-
dence of depression for people with MS is approximately
20%. (5) Overall, 31.7% of our study’s participants reported
depression as a current co-morbidity. The exact propor-
tion meeting diagnostic criteria for depression within this
study population remains unknown. Our sample may be
biased however, as participants in our online survey were
more likely to be engaged in active coping strategies posi-
tively improving their mental health and thereby loweringtheir depression risk compared to the general population
of people with MS who frequently adopt avoidance as a
coping strategy [64].
The PHQ-2 is well validated and rigorous and likely de-
tects those with more severe symptomatology. Although
the PHQ-2 is a short screening tool, the use of two ques-
tions about low mood and anhedonia is a simple and
time-efficient screening tool for depression in MS that can
be easily incorporated into routine care [76].
Reverse causality may contribute to these associations
as depression may result in less healthy behaviours, such
as being sedentary, eating badly, and smoking, perhaps
through low motivation. However, the dose-response ef-
fect for many of the lifestyle variables, and the biological
plausibility of the associations, reduce the likelihood of
reverse causality playing a major role in these findings.
Planned longitudinal follow up of participants may help
clarify causality.
Participants self-reported data so the potential for
measurement error such as recall bias exists, as well as
potential for this error to be correlated between the ex-
posures and outcomes (dependent misclassification) thus
biasing results. The degree to which this is a problem in
our data is not known.
We analysed all types of MS together and there may
be differences in the associations of modifiable risk fac-
tors within subtypes of MS but the smaller sample sizes
within each subtype and the number of variables con-
trolled for in the multivariate analysis would limit the re-
liability of such results.
Our data may be limited as participants required the
cognitive ability to complete the comprehensive survey
and also to have access to the internet. The data can
however be widely generalized given that our sample is
large and geographically diverse and includes people
with all types of MS.Conclusion
This study demonstrates a strong clinically and statisti-
cally significant association between modifiable lifestyle
factors and risk of depression. Diet, smoking, exercise,
omega 3 supplementation, (particularly flaxseed oil),
fish consumption, social support, vitamin D supplemen-
tation, BMI, alcohol intake, meditation and choice of
medication are important modifiable factors in depres-
sion risk for people with MS. It is important for clini-
cians and people with MS to be aware of the wide range
of modifiable lifestyle factors that may reduce depres-
sion risk as part of a comprehensive secondary and ter-
tiary preventive medical approach to managing MS.
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